Precision Medicine in Metastatic Prostate Cancer: FDA Approves PARP Inhibitors for Men with Genetic Mutations
In May, the U.S. Food and Drug Administration (FDA) approved two PARP inhibitors for men with certain genetic mutations and metastatic castration-resistant prostate cancer (mCRPC). The two drugs are olaparib (brand name Lynparza) and rucaparib (brand name Rubraca). Both of…
